{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-093947","form_type":"8-K","ticker":"LCTX","cik":"0000876343","company_name":"Lineage Cell Therapeutics, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.116059+00:00","generated_at":"2026-05-31T11:28:10.710147+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lineage Cell Therapeutics Q2 net loss $5.8M as revenue falls 56% to $1.4M","bullets":["Net loss attributable to Lineage $5.8M ($0.03/share) vs $5.2M prior year; revenue $1.4M vs $3.2M.","Cash and equivalents $38.5M as of June 30; expected to fund operations into Q4 2025.","OpRegen Phase 1/2a data: mean BCVA gain +5.5 letters at 24 months in less advanced GA patients (n=10).","OPC1 spinal cord injury study startup activities ongoing; hosted 2nd Annual SCI Investor Symposium.","Services agreement with Genentech initiated for OpRegen development support, fully funded by Genentech."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-093947","json":"https://secwatch.observer/filing/0000950170-24-093947.json","markdown":"https://secwatch.observer/filing/0000950170-24-093947.md","text":"https://secwatch.observer/filing/0000950170-24-093947.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/876343/000095017024093947/0000950170-24-093947-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/876343/000095017024093947/lctx-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:28:10.710147+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}